MDT-AP-0360
Med · Medulloblastoma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- Med
- cancer_type_detailed
- —
- subtype
- Medulloblastoma
- cancer_type
- Med
- subtype
- Medulloblastoma
- overall_survival_months
- 41.04
- os_event
- false
- age_years
- 10
- sex
- M
- new_clusters
- C2
- umap1_2d
- 2.958874609
- umap2_2d
- 0.72645891
- umap1_3d
- -0.447536567
- umap2_3d
- -3.150019928
- umap3_3d
- -1.583360702
- dataset
- Med-Taylor
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V2+0.480
- WNT_BETA_CATENIN_SIGNALING+0.330
- NOTCH_SIGNALING+0.310
- UNFOLDED_PROTEIN_RESPONSE+0.220
- KRAS_SIGNALING_DN+0.200
- G2M_CHECKPOINT+0.160
- TGF_BETA_SIGNALING+0.130
- MITOTIC_SPINDLE+0.110
- HEME_METABOLISM+0.100
- ESTROGEN_RESPONSE_EARLY+0.090
Top 10 suppressed
- ALLOGRAFT_REJECTION-0.460
- INTERFERON_GAMMA_RESPONSE-0.430
- COMPLEMENT-0.410
- INFLAMMATORY_RESPONSE-0.400
- INTERFERON_ALPHA_RESPONSE-0.370
- TNFA_SIGNALING_VIA_NFKB-0.280
- IL2_STAT5_SIGNALING-0.270
- IL6_JAK_STAT3_SIGNALING-0.260
- KRAS_SIGNALING_UP-0.240
- COAGULATION-0.230
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR11296886 | — | — | 0.869 |
| 2 | MDT-AP-1330 | Med | Medulloblastoma | 0.836 |
| 3 | 167869B6-9620-445E-BA77-B6F95A6463F5 | — | — | 0.820 |
| 4 | TCGA-NC-A5HT-01A-11R-A26W-07 | — | cohortSQ1 | 0.817 |
| 5 | MDT-AP-1100 | Med | Medulloblastoma | 0.808 |
| 6 | DRR168523 | — | — | 0.805 |
| 7 | MDT-AP-0514 | Med | Medulloblastoma | 0.800 |
| 8 | DRR168539 | — | — | 0.796 |
| 9 | MDT-AP-0448 | Med | Medulloblastoma | 0.794 |
| 10 | 20040095.TNBC | — | E | 0.787 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 19 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V2 | 0.480 | Idelalisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.330 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.310 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.220 | Idelalisib | — uncovered |
| KRAS_SIGNALING_DN | 0.200 | Remibrutinib | — uncovered |
| G2M_CHECKPOINT | 0.160 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.130 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.110 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.100 | Temsirolimus | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.090 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.080 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.070 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.070 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.060 | Inavolisib | — uncovered |
| MYOGENESIS | 0.050 | Inavolisib | — uncovered |
| PEROXISOME | 0.040 | Idelalisib | — uncovered |
| UV_RESPONSE_UP | 0.020 | Idelalisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.010 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.010 | Inavolisib | — uncovered |